205 related articles for article (PubMed ID: 18268153)
1. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes.
Fougerat A; Gayral S; Gourdy P; Schambourg A; Rückle T; Schwarz MK; Rommel C; Hirsch E; Arnal JF; Salles JP; Perret B; Breton-Douillon M; Wymann MP; Laffargue M
Circulation; 2008 Mar; 117(10):1310-7. PubMed ID: 18268153
[TBL] [Abstract][Full Text] [Related]
2. Phosphoinositide 3-kinase gamma inhibitor ameliorates concanavalin A-induced hepatic injury in mice.
Wang ZL; Wu XH; Song LF; Wang YS; Hu XH; Luo YF; Chen ZZ; Ke J; Peng XD; He CM; Zhang W; Chen LJ; Wei YQ
Biochem Biophys Res Commun; 2009 Sep; 386(4):569-74. PubMed ID: 19538942
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide-3 kinase gamma activity contributes to sepsis and organ damage by altering neutrophil recruitment.
Martin EL; Souza DG; Fagundes CT; Amaral FA; Assenzio B; Puntorieri V; Del Sorbo L; Fanelli V; Bosco M; Delsedime L; Pinho JF; Lemos VS; Souto FO; Alves-Filho JC; Cunha FQ; Slutsky AS; Ruckle T; Hirsch E; Teixeira MM; Ranieri VM
Am J Respir Crit Care Med; 2010 Sep; 182(6):762-73. PubMed ID: 20508212
[TBL] [Abstract][Full Text] [Related]
4. Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoantibody-induced glomerulonephritis.
Schreiber A; Rolle S; Peripelittchenko L; Rademann J; Schneider W; Luft FC; Kettritz R
Kidney Int; 2010 Jan; 77(2):118-28. PubMed ID: 19907415
[TBL] [Abstract][Full Text] [Related]
5. Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection.
Maus UA; Backi M; Winter C; Srivastava M; Schwarz MK; Rückle T; Paton JC; Briles D; Mack M; Welte T; Maus R; Bohle RM; Seeger W; Rommel C; Hirsch E; Lohmeyer J; Preissner KT
Am J Respir Crit Care Med; 2007 May; 175(9):958-66. PubMed ID: 17322108
[TBL] [Abstract][Full Text] [Related]
6. Dietary alpha-lipoic acid supplementation inhibits atherosclerotic lesion development in apolipoprotein E-deficient and apolipoprotein E/low-density lipoprotein receptor-deficient mice.
Zhang WJ; Bird KE; McMillen TS; LeBoeuf RC; Hagen TM; Frei B
Circulation; 2008 Jan; 117(3):421-8. PubMed ID: 18158360
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice.
Peng XD; Wu XH; Chen LJ; Wang ZL; Hu XH; Song LF; He CM; Luo YF; Chen ZZ; Jin K; Lin HG; Li XL; Wang YS; Wei YQ
J Pharmacol Exp Ther; 2010 Jan; 332(1):46-56. PubMed ID: 19828878
[TBL] [Abstract][Full Text] [Related]
8. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.
Stoll G; Bendszus M
Stroke; 2006 Jul; 37(7):1923-32. PubMed ID: 16741184
[TBL] [Abstract][Full Text] [Related]
9. PI3Kγ Deficient NOD-Mice Are Protected from Diabetes by Restoring the Balance of Regulatory to Effector-T-Cells.
Azzi J; Thueson L; Moore R; Abdoli R; Reijonen H; Abdi R
PLoS One; 2017; 12(1):e0169695. PubMed ID: 28081180
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
[TBL] [Abstract][Full Text] [Related]
11. The effect of pharmacological PI3Kγ inhibitor on eotaxin-induced human eosinophil functions.
Saito Y; Takeda M; Nishikawa J; Konno Y; Tamaki M; Itoga M; Kobayashi Y; Moritoki Y; Ito W; Chihara J; Ueki S
Pulm Pharmacol Ther; 2014 Apr; 27(2):164-9. PubMed ID: 24333185
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-Kinase γ is required for the development of experimental cerebral malaria.
Lacerda-Queiroz N; Brant F; Rodrigues DH; Vago JP; Rachid MA; Sousa LP; Teixeira MM; Teixeira AL
PLoS One; 2015; 10(3):e0119633. PubMed ID: 25775137
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of phosphoinositide 3-kinase γ attenuates inflammation, obesity, and cardiovascular risk factors.
Wymann MP; Solinas G
Ann N Y Acad Sci; 2013 Mar; 1280():44-7. PubMed ID: 23551103
[TBL] [Abstract][Full Text] [Related]
14. [Intervention effect of PI3Kgamma inhibitor AS605240 on autoimmune myocarditis in mice].
Jin K; Song LF; He CM; Wang ZL; Hu XH; Wu XH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):817-20, 825. PubMed ID: 19950590
[TBL] [Abstract][Full Text] [Related]
15. Targeting PI3Kγ activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response.
Smirnova NF; Gayral S; Pedros C; Loirand G; Vaillant N; Malet N; Kassem S; Calise D; Goudounèche D; Wymann MP; Hirsch E; Gadeau AP; Martinez LO; Saoudi A; Laffargue M
J Exp Med; 2014 Aug; 211(9):1779-92. PubMed ID: 25073791
[TBL] [Abstract][Full Text] [Related]
16. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kγ-dependent fluid-phase pinocytosis of native LDL.
Anzinger JJ; Chang J; Xu Q; Barthwal MK; Bohnacker T; Wymann MP; Kruth HS
J Lipid Res; 2012 Jan; 53(1):34-42. PubMed ID: 22058424
[TBL] [Abstract][Full Text] [Related]
17. Phosphoinositide 3-kinase γ plays a critical role in bleomycin-induced pulmonary inflammation and fibrosis in mice.
Russo RC; Garcia CC; Barcelos LS; Rachid MA; Guabiraba R; Roffê E; Souza AL; Sousa LP; Mirolo M; Doni A; Cassali GD; Pinho V; Locati M; Teixeira MM
J Leukoc Biol; 2011 Feb; 89(2):269-82. PubMed ID: 21048214
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis.
Sievers P; Uhlmann L; Korkmaz-Icöz S; Fastner C; Bea F; Blessing E; Katus HA; Preusch MR
Drug Des Devel Ther; 2015; 9():3935-42. PubMed ID: 26251572
[TBL] [Abstract][Full Text] [Related]
19. Mouse models of experimental atherosclerosis.
Jawień J; Nastałek P; Korbut R
J Physiol Pharmacol; 2004 Sep; 55(3):503-17. PubMed ID: 15381823
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3Kγ by AS605240 Protects tMCAO Mice by Attenuating Pro-Inflammatory Signaling and Cytokine Release in Reactive Astrocytes.
Shang S; Liu L; Wu X; Fan F; Hu E; Wang L; Ding Y; Zhang Y; Lu X
Neuroscience; 2019 Sep; 415():107-120. PubMed ID: 31195053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
